|
1
|
Licitra L, Bernier J, Cvitkovic E, Grandi
C, Spinazzé S, Bruzzi P, Gatta G and Molinari R: Cancer of the
nasopharynx. Crit Rev Oncol Hematol. 45:199–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cao SM, Simons MJ and Qian CN: The
prevalence and prevention of nasopharyngeal carcinoma in China.
Chin J Cancer. 30:114–119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma BB, Hui EP and Chan AT: Systemic
approach to improving treatment outcome in nasopharyngeal
carcinoma: Current and future directions. Cancer Sci. 99:1311–1318.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiao WW, Huang SM, Han F, Wu SX, Lu LX,
Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival,
and late toxicities of locally advanced nasopharyngeal carcinoma
treated by simultaneous modulated accelerated radiotherapy combined
with cisplatin concurrent chemotherapy: Long-term results of a
phase 2 study. Cancer. 117:1874–1883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM
and Soefje SA: Clinical evaluation of compounds targeting
PD-1/PD-L1 pathway for cancer immunotherapy. J Oncol Pharm Pract.
21:451–467. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zou W and Chen L: Inhibitory B7-family
molecules in the tumour microenvironment. Nat Rev Immunol.
8:467–477. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flies DB and Chen L: The new B7s: Playing
a pivotal role in tumor immunity. J Immunother. 30:251–260. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Muenst S, Schaerli AR, Gao F, Däster S,
Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE,
et al: Expression of programmed death ligand 1 (PD-L1) is
associated with poor prognosis in human breast cancer. Breast
Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Thompson RH, Kuntz SM, Leibovich BC, Dong
H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H,
et al: Tumor B7-H1 is associated with poor prognosis in renal cell
carcinoma patients with long-term follow-up. Cancer Res.
66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chua DT, Sham JS, Wei WI, Ho WK and Au GK:
The predictive value of the 1997 American joint committee on cancer
stage classification in determining failure patterns in
nasopharyngeal carcinoma. Cancer. 92:2845–2855. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dolan DE and Gupta S: PD-1 pathway
inhibitors: Changing he landscape of cancer immunotherapy. Cancer
Control. 21:231–237. 2014.PubMed/NCBI
|
|
15
|
Chen BJ, Chapuy B, Ouyang J, Sun HH,
Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA and Rodig
SJ: PD-L1 expression is characteristic of a subset of aggressive
B-cell lymphomas and virus-associated malignancies. Clin Cancer
Res. 19:3462–3473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin X, Gudgeon NH, Hui EP, Jia H, Qun X,
Taylor GS, Barnardo MC, Lin CK, Rickinson AB and Chan AT: CD4 and
CD8 T cell responses to tumour-associated Epstein-Barr virus
antigens in nasopharyngeal carcinoma patients. Cancer Immunol
Immunother. 57:963–975. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li HP, Peng CC, Chung IC, Huang MY, Huang
ST, Chen CC, Chang KP, Hsu CL and Chang YS: Aberrantly
hypermethylated Homeobox A2 derepresses metallo proteinase-9
through TBP and promotes invasion in Nasopharyngeal carcinoma.
Oncotarget. 4:2154–2165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Teixido C, Karachaliou N, González-Cao M,
Morales-Espinosa D and Rosell R: Assays for predicting and
monitoring responses to lung cancer immunotherapy. Cancer Biol Med.
12:87–95. 2015.PubMed/NCBI
|
|
20
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
D'Incecco A, Andreozzi M, Ludovini V,
Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J,
Coppi E, et al: PD-1 and PD-L1 expression in molecularly selected
non-small-cell lung cancer patients. Br J Cancer. 112:95–102. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. N Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang W, Zhang J, Hong S, Zhan J, Chen N,
Qin T, Tang Y, Zhang Y, Kang S, Zhou T, et al: EBV-driven LMP1 and
IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications
for oncotargeted therapy. Oncotarget. 5:12189–12202. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thompson RH, Dong H and Kwon ED:
Implications of B7-H1 expression in clear cell carcinoma of the
kidney for prognostication and therapy. Clin Cancer Res.
13:709s–715s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang
JY, Yang YP, Tien P and Wang FS: PD-1 and PD-L1 upregulation
promotes CD8(+) T-cell apoptosis and postoperative recurrence in
hepatocellular carcinoma patients. Int J Cancer. 128:887–896. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ghebeh H, Tulbah A, Mohammed S, Elkum N,
Bin Amer SM, Al-Tweigeri T and Dermime S: Expression of B7-H1 in
breast cancer patients is strongly associated with high
proliferative Ki-67-expressing tumor cells. Int J Cancer.
121:751–758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muenst S, Soysal SD, Gao F, Obermann EC,
Oertli D and Gillanders WE: The presence of programmed death 1
(PD-1)-positive tumor-infiltrating lymphocytes is associated with
poor prognosis in human breast cancer. Breast Cancer Res Treat.
139:667–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Marzec M, Zhang Q, Goradia A, Raghunath
PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA and
Wasik MA: Oncogenic kinase NPM/ALK induces through STAT3 expression
of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad
Sci USA. 105:20852–20857. 2008. View Article : Google Scholar : PubMed/NCBI
|
